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The expression of prostate-specific membrane antigen (PSMA) and prostate-specific antigen
(PSA), two well characterized marker proteins, remains highly active in the hormone refractory
stage of prostate cancer. In this study, an artificial chimeric enhancer (PSES) composed of two
modified regulatory elements controlling the expression of PSA and PSMA genes was tested for
its promoter activity and tissue specificity using the reporter system. As a result, this novel PSES
promoter remained silent in PSA- and PSMA-negative prostate and non-prostate cancer cell lines,
but mediated high levels of luciferase in PSA- and PSMA-expressing prostate cancer cell lines in
the presence and absence of androgen. To determine whether PSES could be used for in vivo
gene therapy of prostate cancer, a recombinant adenovirus, Ad-PSES-luc, was constructed.
Luciferase activity in prostate cancer cell lines mediated by Ad-PSES-luc was 400- to 1000-fold
higher than in several other non-prostate cell lines, suggesting the high tissue-specificity of the
PSES promoter in an adenoviral vector. Finally, recombinant virus Ad-PSES-luc was injected into
mice to evaluate the tissue-discriminatory promoter activity in an experimental animal. Unlike
Ad-CMV-luc, the luciferase activity from systemic injection of Ad-PSES-luc was fairly low in all major
organs. However, when injected into prostate, Ad-PSES-luc drove high luciferase activity almost
exclusively in prostate and not in other tissues. Our results demonstrated the potential use of
PSES for the treatment of androgen-independent prostate cancer patients.
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ARTICLEINTRODUCTION
Prostate cancer is the second leading cause of cancer death
in men annually [1]. Initially, prostate cancer develop-
ment is androgen-dependent. However, it evolves to an
androgen-independent stage by unknown molecular
mechanisms and becomes refractory to hormone ablation
therapy. Currently, there are no effective therapeutic
agents available for patients with hormone-refractory
prostate cancer.
Among several prostate-specific proteins, prostate-spe-
cific antigen (PSA) and prostate-specific membrane antigen
(PSMA) are sensitive markers for prostate cancer diagnosis
and progression. PSA is a serine protease produced by the
prostatic ductal epithelial cells and secreted into the semi-
nal plasma. The basement membrane acts as a barrier to
block PSA from escaping into systemic circulation. Prostate
cancer or benign hyperplasia disrupts the membrane, elicit-
ing significant increases in serum PSA. Therefore, serum PSA
is used as a molecular marker for prostate abnormalities.MOLECULAR THERAPY Vol. 6, No. 3, September 2002
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1525-0016/02  $35.00PSA expression is modulated by androgens, acting
through androgen receptor (AR) like other nuclear recep-
tor families [2]. Upon binding androgen, primed AR is
translocated into the nucleus and binds the proximal pro-
moter and enhancer core region (AREc) 4.2 kb upstream
of the PSA gene [3–5]. The PSA regulatory element or its
modification exhibits strong tissue-specific activity and
has been used to drive therapeutic gene expression tar-
geting prostate cancer [6,7]. The transcriptional levels
mediated by PSA promoters are, however, significantly
lower in the absence of androgen, which potentially lim-
its its application in patients under androgen ablation
therapy. Transcription levels must be improved for effec-
tive therapeutic results; a highly active promoter with
stringent tissue-specificity is crucial for delivering foreign
DNA to target tissue.
PSMA was discovered as a membrane antigen reactive to
monoclonal antibody 7E11-C5 [8]. The physiological role of
PSMA in prostate remains unknown. It has hydrolase 415
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promoter. (A) Sequence of the 440-bp AREc in the 4.2 kb upstream of PSA
promoter. Linker-scanning mutations were introduced in the pGL3/AREc/TATA
construct [16] by substituting 17 bp with a GAL4 binding sequence (under-
lined). Mutants were named L14 to R10. (B) LNCaP (2  105 cells) seeded in
12-well plates were transfected with 0.5 g of each construct. We added 3
nM of androgen R1881 when the transfection medium was changed 5 hours
after transfection. We cotransfected 1 ng of Renilla luciferase vector, pRL-SV40
(Promega), to monitor transfectional efficiency. Firefly and Renilla luciferase
activities were determined using the Dual Luciferase Reporter System
(Promega). Results are presented as mean ± SD of three transfections. (C) The
region ranging from L7 to R3 was placed upstream of an artificial TATA box
to make a new construct AREc3 (pGL3/AREc3/TATA). The transcriptional activ-
ity of pGL3/AREc3/TATA was compared with PSA promoter (pGL3/p61/TATA)




enzymatic activity with the substrates of folate and N-acety-
laspartylglutamate (NAAG) [9,10]. Serum PSMA in prostate
cancer is significantly higher than for benign prostate hyper-
plasia or normal prostate, suggesting enhanced expression
of PSMA as prostate cancer progresses [11]. Furthermore,
because the level of PSMA expression is downregulated by
androgen, patients undergoing hormone ablation therapy
exhibit increasing expression of serum PSMA [12].
PSMA expression is controlled by two characterized reg-
ulatory elements. The proximal 1.2-kb promoter upstream
of the gene that encodes PSMA (FOLH1) drives reporter
gene expression but with less tissue-specificity than the
PSA promoter [13]. Recently, PSMA enhancer (PSME) was
found to be located within the third intron of FOLH1, con-
ferring the prostate-specific expression of PSMA [14]. Its416tissue-specificity and upregulation in the
absence of androgen enabled PSME to be
used for expressing a toxic gene exclusively
in the prostate in an androgen-depleted envi-
ronment [15].
We investigated the hypothesis that fac-
tors that transactivate AREc and PSME could
function together synergistically. Through
deletion and linker scan mutagenesis, we
located the minimal sequences, AREc3 and
PSME (del2) in AREc and PSME, respectively,
that retained high prostate-specific activity.
A combination of AREc3 and PSME (del2),called PSES, demonstrated synergistic and prostate-specific
transcriptional activity. This novel promoter could be of
great benefit to gene therapy for metastatic prostate can-
cer in the absence of androgen.
RESULTS AND DISCUSSION
AREc3 and PSME (del2), Derived from AREc 
and PSME, Respectively, Exhibit Strong 
Prostate-Specific Activity
AREc is located upstream of the PSA promoter, allowing the
high expression of PSA in a tissue-specific manner [3,4,16].
We constructed 25 linker scanning mutants within the
AREc region to analyze important cis-elements (Fig. 1A).
Several linker mutants (L1, L3, L4, L6, L7, R1, R2, and R3)
showed a clear and significant decrease in transcriptional
activity (Fig. 1B), indicating the existence of an activator
element located between positions L7 and R3. To evaluate
the promoter activity mediated by the fragment (AREc3)
containing GATA sites within the L7 to R3 region, AREc3
was cloned in the luciferase reporter system and compared
with AREc and the 5.8-kb PSA promoter p61 [16]. AREc3
activity was 5.7-fold higher than that of p61 and 24-fold
higher than that of AREc in the presence of androgen (Fig.
1C). However, all constructs had a basal promoter activity
in the absence of androgen (data not shown). AREc3
appears to have high enhancer activity due to deletion of
potential silencers outside the AREc3 region. AREc3 hasMOLECULAR THERAPY Vol. 6, No. 3, September 2002
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both the 90-bp upstream enhancer and
the Alu repeat silencer (Fig. 2B), had
activity that was moderately higher than
that of PSME (del3) but lower than that
of PSME (del2), reflecting the overall
level of promoter activity without silenc-
ing or enhancing regulatory elements in
the regions of deletion of bp 1–90 and bp
262–327, respectively.
All PSME deletions shown in Fig. 2B
showed downregulation in the presence
of androgen, suggesting that the regula-
tory element responsible for androgen-
mediated downregulation of PSME activ-
FIG. 2. Deletion analysis of PSME. (A) Sequence of PSME located in the third
intron in the PSMA gene (FOLH1). PSME contains nine AP-1 sites, a repeat
sequence (bold), and an Alu sequence (lower case). (B) Left panel schematically
illustrates the deletions of PSME used in this study. The shortened versions of
PSME were inserted upstream of TATA in pGL3/TATA. The transcriptional activ-
ities of these constructs were then evaluated by transient reporter assay as
described in Fig. 1. Results are presented as mean ± SD.
A
B
three AR binding sites and six GATA transcription factor
binding sites, suggesting that GATA is involved in the opti-
mal androgen induction.
PSME, which is within the third intron of the PSMA-
encoding gene, enables the prostate-specific gene expres-
sion of PSMA in the absence of androgen [14]. We con-
structed a series of deletions to further locate
prostate-specific enhancers within PSME (Fig. 2A) and
evaluated their enhancing activities. PSME (del2), which
lost the Alu-repeat sequence (262 to 327 bp) located at the
end of PSME, had four- to fivefold higher activity than
PSME, suggesting that the Alu repeat contains a suppres-
sive regulatory element (Fig. 2B). The Alu repeat belongs
to the SINE (short interspersed element) family of human
repetitive sequences [17]. Although the function of Alu-
repeat sequences is not well understood, several studies
have identified transcriptional silencers within Alu-repeat
sequences and suggested that Alu-repeat sequences might
be involved in transcriptional regulation [17]. This study
provides additional data suggesting a role for Alu-repeat
sequences in gene regulation.
In contrast to PSME (del2), PSME (del3), which lacks bp
1–90, had much lower promoter activity compared with
the full-length PSME, indicating that this region upstream
of direct repeat sequences (Fig. 2A) harbors one or more
enhancer elements. According to sequence analysis, this
upstream region of PSME, bp 1–90, includes an activator
protein 1 (AP-1) binding site and three AP-3 binding sites
(Fig. 2A). These potential regulators may be involved in the
transcriptional activation of PSMA gene expression.MOLECULAR THERAPY Vol. 6, No. 3, September 2002
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Interestingly, AR was demonstrated to inhibit c-Jun/AP-1
site interaction by forming a complex with c-Jun without
directly binding to the AP-1 site [18]. Because there are
nine AP-1 sites within and upstream of the direct repeat
sequence, AP-1s may act as positive regulators and their
activities may be downregulated by androgen.
PSA promoter, which has been investigated for prostate
cancer gene therapy [6,7], is a tissue-specific promoter
whose activity heavily depends on androgens. We reported
that PSA promoter had higher activity in androgen-inde-
pendent C4-2 cells than in androgen-dependent LNCaP
cells in the absence of androgen [16]. However, its activ-
ity in C4-2 cells in the absence of androgen is still much
weaker than that of the commonly used simian virus 40
(SV40) or Rous sarcoma virus (RSV) promoters. This lower
level of promoter activity potentially hampers its applica-
tion in patients for androgen ablation therapy. On the
other hand, the enhancer activity of PSME (del2) was
higher in the absence of androgen but still significantly
lower compared with constitutively active viral promoters.
We believed that both AREc3 and PSME (del2) were likely
to function weakly in patients under androgen ablation
therapy due to the patients’ low levels of androgen and to
AR mutation or amplification, which resulted in partial
activation of AREc3 and suppression of PSME (del2) activ-
ity (unpublished data). We hypothesized that the combi-
nation of AREc3 and PSME (del2) might have a synergis-
tic enhancer effect, balance out the positive and negative
regulatory effect of androgen, and retain tissue specificity.417
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promoter was constructed by placing AREc3 fragment upstream of PSME in
pGL3/PSME/TATA to make pGL3/PSES/TATA. Likewise, AREc3 fragment was inserted
upstream of PSME(del2) in pGL3/PSME(del2)/TATA to make pGL3/PSES/TATA. We
transfected 0.5 g of pGL3/TATA containing PSME, AREc3/PSME, AREc3 PSME (del2),
or PSES, as indicated, along with pRL-SV40 for luciferase activities, and the luciferase
activity was determined. (B) We transfected 0.5 g of each plasmid and determined
luciferase activity. This experiment was also conducted in the absence of androgen.
Results are presented as mean ± SD. (C) We transfected 0.5 g of pGL3/PSES/TATA into
various cell lines (2  105 cells for each). This experiment was conducted in the absence
of androgen. The luciferase activity was determined by division by the basal activity rep-
resented by transfection of pGL3/TATA. Results are presented as mean ± SD.
A B
C
PSES Synergistically Drives Gene Expression 
in a Prostate-Specific Manner
We constructed a chimeric promoter composed of AREc3
and PSME (del2), called prostate-specific enhancing
sequence (PSES; Fig. 3A). Evaluation of its promoter activ-
ity is shown in Fig. 3B. The level of luciferase activity
driven by PSES was approximately fivefold higher than
RSV promoter-mediated luciferase activity. As expected,
promoter activity of PSES was greater than the sum of the
promoter activities of AREc3 and PSME (del2), suggesting
that transcription regulators in AREc3 and PSME (del2)
cooperated synergistically to drive a high level of gene
expression. Yet, the addition of PSME to AREc3 elicited a
negative effect on the promoter activity of AREc3. The Alu
repeat appears to interfere with the AR-induced transcrip-
tional enhancement of AREc3 by an unknown mecha-
nism.
Although the potency of a promoter is important for
gene-therapy purposes, tissue specificity is also critical for
avoiding potential nonspecific side effects. The tissue speci-
ficity of PSES was tested in several different cell lines. PSES
drove a high level of luciferase expression in the PSA- and
PSMA-expressing prostate cancer cells LNCaP, C4-2, and
CWR22rv (Fig. 3C). However, its activity in non-prostate418cancer cells and the PSMA-negative prostate cancer cells PC-
3 and DU145 was negligible, suggesting that PSES retained
tissue specificity like PSA and PSME enhancers.
PSES Retained Tissue Specificity in an 
Adenoviral Vector
Adenoviral vectors have been extensively investigated as
anti-tumor reagents, demonstrating real promise for
prostate cancer gene-therapy [19]. To evaluate the poten-
tial application of PSES for gene-therapy, we constructed
a recombinant adenovirus, Ad-PSES-luc, carrying the
luciferase gene under the control of PSES (Fig. 4A). We
tested whether PSES would exhibit prostate-specific activ-
ity in a recombinant adenovirus form. Ad-PSES-luc was
prepared and used to infect several different cell types.
PSES was more active in PSA- and PSMA-positive prostate
cancer cells by 400- to 1000-fold compared with PSA- and
PSMA-negative prostate cancer cells (for example, PC-3
and DU145) or with non-prostate cancer cells, demon-
strating that PSES retained tissue specificity in a recombi-
nant adenoviral vector (Fig. 4B).
To evaluate the tissue-discriminatory promoter activity
of PSES in an experimental animal, BALB/c nude mice were
injected with 2.0  109 virus particles of Ad-CMV-luc, MOLECULAR THERAPY Vol. 6, No. 3, September 2002
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illustration of recombinant adenovirus Ad-PSES-luc. PA, poly-adenylation site. (B)
Different cell lines (2  105 cells for each) seeded in 12-well plates were infected
by adenoviruses Ad-RSV--Gal and Ad-PSES-luc (100 virus particles per cell of
each virus) for 8 hours, and media were replaced with RPMI 1640 supplemented
with 5% charcoal-stripped serum (without androgen). After 2 days, cells were
harvested, lysed with passive lysis buffer (Promega), and analyzed for luciferase
and -galactosidase activities. The luciferase activities are normalized with -
galactosidase activity. Results are presented as mean ± SD.
A Bcarrying the luciferase gene under the control of the
cytomegalovirus (CMV) promoter, or Ad-PSES-luc. After 3
days, we measured the luciferase expression in different
mouse organs. High levels of luciferase activity were
detected predominantly in liver, spleen, and lung, but lev-
els were negligible in other tissues obtained from mice
injected with Ad-CMV-luc(Fig. 5A). Unlike Ad-CMV-luc,
Ad-PSES-luc was inactive in all organs tested. However,
when injected directly into prostate (Fig. 5B), Ad-PSES-luc
was highly active in prostate. These data demonstrated that
PSES in the form of Ad-PSES-luc was active in normal
mouse prostate with high tissue specificity.
In this study, we developed a novel prostate-specific
chimeric enhancer, PSES, from the enhancer cores of PSA
promoter, AREc3, and PSME (del2). This PSES was highly
active in PSA- and PSMA-positive prostate cancer cells in
the presence and absence of androgens, exhibiting strong
tissue-specificity as an adenoviral vector. Its strong andro-
gen-independent promoter activity makes PSES superior to
PSA and PSMA promoters for the treatment of patients
undergoing androgen ablation therapy.FIG. 5. PSES promoter in the form of Ad-PSES-
luc remains specifically active in the prostate of
in vivo mice. (A) We injected 7  1010 virus
particles of recombinant virus Ad-CMV-luc
(filled bar) or Ad-PSES-luc (open bar) into tail
veins of male athymic mice. After 2 days,
organs were harvested from sacrificed mice
and homogenized. Protein extracts (0.48 mg)
were used to determine luciferase activities.
(B) We injected 1.4  1010 virus particles of
recombinant virus Ad-CMV-luc (filled bar) or
Ad-PSES-luc (open bar) into prostates of male
athymic mice. Protein extracts were obtained
and used as described for luciferase activities.
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the replication-competent oncolytic adenovirus for the
treatment of androgen-independent prostate cancer.
Although PSA enhancer and promoter were used to drive
the prostate-specific replication of oncolytic adenoviruses
[20], we believe that PSES-based replication-competent ade-
novirus would be more efficacious for the treatment of
androgen-independent prostate cancer.
MATERIALS AND METHODS
Cells and cell culture. LNCaP, C4-2, CWR22rv, PC-3, and DU145 prostate
cancer cell lines were maintained in T medium supplemented with 5% fetal
bovine serum (FBS) and 1% penicillin/streptomycin (P/S). C4-2 was pur-
chased from Urocore (Oklahoma City, OK). CWR22rv was obtained from
Liang Cheng (Indiana University). LNCaP was obtained from Leland Chung
(Emory University). Human liver carcinoma HepG2, human cervix cancer
cell line HeLa, human testicular cancer cell line Tera-1, human kidney can-
cer cell line RCC-29, human colon cancer cell line HT-29, human osteoblast-
derived osteosarcoma cell line MG63, and human prostate cancer cell lines
PC-3 and DU145 were purchased from American Type Culture Collection
(Rockville, MD) and maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% FBS and 1% P/S.419
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tion using a BAC clone from Genome Systems (St. Louis, MO) as a substrate
and two primers, 5-TTAGGCTAGCAATTATTTTTTCCTTTAACCTT-3 and
5-ATCCCCCGGGAGGCGGAGGTTGCAGTGAGC-3. PCR-amplified frag-
ments were digested with NheI and SmaI and ligated into the same sites of
pGL3/TATA [16]. PSME deletions were generated by PCR technology.
Forward primers for PCR amplification were 5-TTAGGCTAGCAAT-
TATTTTTTCCTTTAACCTT-3 for PSME (del2), and 5-TTAGGCTAGCCTT-
TATTGGTTGTAATATTGACT-3 for PSME (del3) and PSME (del4). Backward
primers were 5-ATCCCCCGGGAGGCGGAGGTTGCAGTGAGC-3 for
PSME (del3), and 5-ATCCCCCGGGAAAACAACAAAAAAATCTAG-3 for
PSME (del2) and PSME (del4). PCR-amplified fragments were digested with
NheI and SmaI and ligated into the equivalent site of pGL3/TATA vector
(Promega, Madison, WI). PSES was constructed by digesting PSME (del2)
with NheI and SmaI and inserting the resultant DNA fragment into
pGL3/AREc3/TATA digested with NheI and SmaI restriction enzymes.
PSA promoter derivatives were constructed. AREc DNA fragments were
prepared by PCR-amplification of p61 [16] using two primers, 5-GGTAC-
CCCTAGGGGTGACCAGAGCAGTCTA-3 and 5-GCTAGCAGA-
CAAGGGTGGAAGCCT-3, subcloned into a TOPO cloning vector
(Invitrogen, Carlsbad, CA). The resulting TOPO vector containing AREc
was digested with KpnI and NheI and ligated into pGL3/TATA cut with
KpnI and NheI. The pGL3/AREc3/TATA was prepared by digesting PCR-
amplified fragments with KpnI and NheI and inserting them into
pGL3/TATA cut with the same enzymes. Amplification was performed
using pGL3/AREc/TATA as a template and two primers, 5-GGTACCCC-
TAGGAGATATTATCTTCATGATC-3 and 5-GCTAGCTTCAAGGAT-
GTTTGTAAGC-3. All constructs used in this study were confirmed by
sequence analysis.
Linker scanning mutagenesis. For linker scanning analysis of AREc, 25
linker mutants, derived from pGL3/AREc/TATA, were generated as
described [16]. These plasmids carry linker-scan mutants that were intro-
duced in the  pGL3/AREc/TATA by replacing 17 bp with GAL4-binding
site (5-CGGAGTACTGTCCTCCG-3). The forward primers and reverse
primers contain half of the GAL4-binding site, 5-GTCCTCCG-3 and 5-
AGTACTCCG-3 at the 5 end, followed by 20 bp of AREc adjacent to the
mutagenized bases. PCR reactions were carried out with 100 pg of
pGL3/AREc/TATA as a template. The PCR products were purified from a
0.8% agarose gel and ligated with a rapid ligation kit (Roche, Indianapolis,
IN) following the manufacturer’s protocol. Clones were screened by PCR
for the presence of a GAL4-binding site and Glprimer2 from the pGL3-
basic vector (Promega). If a mutant demonstrated a 20% higher or lower
activity than AREc, it was subcloned back to pGL3/TATA to exclude the
possibility that the effect was due to nonspecific PCR mutation.
Transient transfection for luciferase and -galactosidase assays. For
transient transfections, 1  105 cells/well were plated in 12-well plates for
24 hours. Plasmid DNAs were delivered into cells with DOTAP (Roche) fol-
lowing the manufacturer’s protocol. Briefly, 0.5–1 g of tested plasmid
DNA was mixed with lipid at room temperature before addition to a well
containing 1 ml of serum-free and phenol red-free RPMI 1640 medium.
After 15 minutes, DNA-lipid complexes were added to the well and incu-
bated for 5 hours at 5% CO2 and 37C. DNA-lipid containing medium was
then replaced with 1 ml of serum-free and phenol red-free RPMI 1640
medium containing 5% charcoal stripped serum and 1% P/S, with or with-
out 3 nM of androgen (R1881). After 2 days, cells were collected and lysed
in 250 l passive lysis buffer (Promega). Cell lysates were vortexed for a few
seconds and spun for 3 minutes. For dual luciferase activity detection, 10
l of the supernatant was mixed with 50 l of luciferase substrate (Promega)
and measured with a femtometer (Zylux, Germany). Subsequently, 50 l
of stop solution (Promega) was added to the tube, mixed, and measured
with a luminometer for the Renilla luciferase activity. -Galactosidase activ-
ity was determined with a femtometer by mixing 20 l of the supernatant
with 200 l of substrate (Tropix, Bedford, MA) and incubating at 37C for
30 minutes (Zylux, Germany). Data are expressed as relative luciferase activ-
ity, defined as luciferase activity normalized to internal control CMV/-
galactosidase activity for viral luciferase activity or to SV40/Renilla for dual
luciferase activity. Relative luminescence is expressed as the mean ± stan-
dard error of the mean of at least three independent experiments.420Virus construction. Recombinant Ad-PSES-luc was constructed (Fig. 4A).
Briefly, a KpnI/BamHI fragment containing a PSES-luc expression cassette
from pGL3/PSES/TATA was subcloned into pAd1020sfidA (a gift from
Xavier Denthinne, OD 260, Inc., Boise, ID) digested with the same restric-
tion enzymes. pAd1020sfidA contains adenovirus left ITR and packaging
signal (bp 1–358). After cloning the expression cassette into
pAd1020sfidA, the left arm of the adenovirus with the expression cassette
was cut out by digestion with SfiI and PacI and ligation to the SfiI-PacI
adenovirus left arm called AdenoZapsfi.2 (OD 260) in the presence of PacI.
The ligation mixture was precipitated and transfected into 293 cells with
lipofectamine (GIBCO, Rockville, MD) following the manufacturer’s pro-
tocol. The cells were passed from 24-well to 6-well growth conditions and
covered with 0.6% agarose 2 days after transfection. Several selected
clones were obtained by at least three rounds of plaque isolation as
described [21]. One clone was propagated in 293 cells, purified by CsCl2
gradient centrifugation, and dialyzed against 10 mM Tris-HCl (pH 7.5)/1
mM MgCl2 buffer supplemented with 10% glycerol. The viral titer was
determined by measuring the optical density at 260 nm after lysing viral
particles in 5% SDS. The control viruses Ad-RSV--Gal and Ad-CMV-luc
were prepared as described [21].
In vivo animal experiments. BALB/c nude mice were injected through
the tail vein with 7.5  1010 virus particles of Ad-CMV-luc or Ad-PSES-
luc. For intra-prostatic injection, 7.5  109 virus particles of Ad-CMV-luc
or Ad-PSES-luc were used. Animals were sacrificed and their major organs
were collected. We homogenized organs in 1 ml of 1 passive lysis buffer
(Promega) supplemented with protease inhibitor cocktails using a
PowerGen 125 (Polytron Kinematica, Switzerland) 3 days after virus injec-
tion. We analyzed the resultant 50 l of lysate for luciferase activity.
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